AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
SUZHOU, China I March 5, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer ...
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set ... Hutchmed's drug is also being paired with Tagrisso and AZ's PD-L1 blocker Imfinzi (durvalumab) in global ...
Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback